Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 11/20 | 0.38 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636946 | 0.92 | IL2 (0.46) | IL2STIM1ORAI1ORAI2SCN5A | |
| SCHEMBL16636932 | 0.89 | SCN9A (0.36) | IL2SCN5ASCN9ABRAF | |
| SCHEMBL16636432 | 0.89 | IL2 (0.39) | IL2STIM1ORAI1ORAI2SCN5A | |
| SCHEMBL16636766 | 0.89 | STIM1 (0.40) | IL2STIM1ORAI1ORAI2SCN9A | |
| SCHEMBL16636870 | 0.88 | IL2 (0.37) | IL2STIM1ORAI1ORAI2SCN5A | |
| SCHEMBL16636954 | 0.84 | MEN1 (0.37) | IL2STIM1ORAI1BRAF | |
| SCHEMBL16637357 | 0.84 | IL2 (0.35) | IL2STIM1ORAI1ORAI2BRAF | |
| SCHEMBL16636678 | 0.83 | IL2 (0.42) | IL2STIM1ORAI1ORAI2SCN9A | |
| SCHEMBL16636507 | 0.82 | CYP1A2 (0.38) | BRAF | |
| SCHEMBL16636740 | 0.82 | NPC1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611263-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-08-11 | — | — | US | disclosed |
| WO-2015054283-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | IL2 3716/4885STIM1 17/4885ORAI1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.